Interleukin-1 response to arterial antigen, lipopolysaccharide, and oxidized low density lipoprotein in ischemic heart disease

Journal of Investigative Medicine

Volumn 45, Issue 8, 1997, Pages 474-482

  Grasing, Kenneth ^a   Rifici, Vincent ^a   Patel, Mungal ^a   Patel, Amrish ^a   Dennis, Reginald ^a   Kostis, John B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Arterial antigen; Interleukin 1; Ischemic heart disease; Peripheral blood mononuclear cells; Proliferation

Indexed keywords

ANTIGEN; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MITOGENIC AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOLOGY; INTIMA; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; OXIDATION REDUCTION REACTION;

ADULT; ANTIGENS; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; MITOGENS; MONOCYTES; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; TUNICA INTIMA;

ANGINA;

EID: 0031255694     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Boraschi D, Villa L, Volpini G, Bossu P, Cesini S, Ghiara P, Scapigliat G, Nencioni L. Bartalini M, Matteucci G. Differential activity of interleukin 1-alpha and interleukin 1-beta in the stimulation of the immune response in vivo, Eur J Immunol 1990;20:317-21.
2. Djeu JY. Monocyte/macrophage functions. In: Rose NR, de Macario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology, 4th ed. Washington, DC: American Society for Microbiology, 1992:231-5.
3. di Giovine FS, Duff GW. Interleukin 1: the first interleukin. Immunol Today 1990;11:13-20.
4. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current protocols in immunology, vol I. New York: Greene Publishing Associates and Wiley-Interscience, 1992.
5. Poole S, Bristow AF, Selkirk S, Rafferty B. Development and application of radioimmunoassays for interleukin 1-alpha and interleukin 1-beta. J Immunol Methods 1989;116:259-64.
6. Dinarello CA. Interleukin 1 and tumor necrosis factor: effector cytokines in autoimmune diseases. Immunology 1992;4:133-45.
7. Dejana E, Breviario F, Erroi A, Bussolino F, Mussoni L, Gramse M, Pintucci G, Casali B, Dinarello CA, Van Damme J, Mantovani A. Modulation of endothelial cell functions by different molecular species of interleukin 1. Blood 1987;69:695-9.
8. Montesano R, Orci L, Vassalli P. Human endothelial cell cultures: phenotypic modulation by leukocyte interleukins. J Cell Physiol 1985;122:424-34.
9. Libby P, Warner SJC, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988;81:487-98.
10. Libby P, Ordovas JM, Birinyi LK, Auger KR, Dinarello CA. Inducible interleukin 1 gene expression in human vascular smooth muscle cells. J Clin Invest 1986;78:1432-8.
11. Warner SJC, Autger KR, Libby P. Human interleukin 1 induces interleukin gene expression in human vascular smooth muscle cells. J Exper Med 1987;165:1316-31.
12. Raines EW, Dower SK, Ross R. Interleukin 1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989;243:393-5.
13. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Maiden LT, Masuko H, Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenisis. Science 1990;248:1009-12.
14. Nakamura M, Saito H, Kasanuki J, Tamura Y, Yoshida S. Cytokine production in patients with inflamatory bowel disease. Gut 1992;33:933-7.
15. Ruschen S, Lemm G, Warnatz H. Spontaneous and LPS-stimulated production of intracellular IL-1β by synovial macrophages in rheumatoid arthritis is inhibited by IFN-γ. Clin Exper Immunol 1989;76:246-51.
16. Umehara H, Kamagai S, Murakami M, Suginoshita T, Tanaka K, Hashida S, Ishikawa E, Imura H. Enhanced production of interleukin 1 and tumor necrosis factor alpha by a cultured peripheral blood monocyte from patients with scleroderma. Arthritis Rheum 1993;33:893-7.
17. Nakao S, Matsushima K, Young N. Decreased interleukin 1 production in aplastic anaemia. Br J Haematol 1989;71:431-6.
18. Leung DYM, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and high interleukin 1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989;1:1298-302.
19. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin 2 secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992;327:1613-7.
20. Rifici VA, Khachadurian AK. The inhibitor of low density liprotein oxidation by 17-Beta estradiol. Metabolism 1992;41:110-1.
21. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T-cell activation by oxidized low denisity lipoprotein. Arterioscler Thromb 1992;12:461-7.
22. Ofosu-Appiah W, Ruggiero C, Huang L. Isolation of T-cell clones with specificity for arterial antigen from spontaneously hypertensive rats. J Hypertens 1993;11:1319-28.
23. Nurminen M, Leinonen M, Saikku P, Makela PH. The genus-specific antigen of chlamydia: resemblance to the Lipopolysaccharide of enteric bacteria. Science 1983;220:1279-81.
24. Miller LE, Ludke HR, Peacock JE, Tomar RH. Manual of laboratory immunology. Philadelphia: Lea & Febiger, 1991.
25. Zar JH. Biostatistical analysis. Englewood Cliffs, (NJ): Prentice Hall, 1984.
26. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis 1984;53:265-71.
27. Emeson EE, Robertson AL. T lymphocytes in aortic and coronary intima, their potential role in atherogenesis. Amer J Pathol 1988;130:369-76.
28. Annand JC. Denatured bovine immunoglobin pathogenic to atherosclerosis. Atherosclerosis 1986;59:347-51.
29. Hamsten A, Norberg R, Björkholm M, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;1:113-6.
30. Cerilli J, Brasile L, Karmody A. Role of the vascular endothelial cell antigen system in the etiology of atherosclerosis. Ann Surg 1985;202:329-33.
31. Kostis JB, Turkevich D, Sharp J. Association between leukocyte count and the presence and extent of coronary atheroscerosis as determined by coronary arteriography. Amer J Cardiol 1984;53:997-9.
32. Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974;290:1275-8.
33. Blum A, Schlarovsky S, Shohat B. T lymphocyte activation in stable angina pectoris and after percutaneous transluminal coronary angioplasty. Circulation 1995;91:20-2.
34. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of c-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
35. Willard JE, Lange R, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1997;327:175-61.
36. Vaddi K, Nicolini FA, Mehta P, Mehta JL. Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease - relevance in superoxide anion generation. Circulation 1994;90:694-9.
37. Gudbrandsson T, Hannson L, Herlitz H, Lindholm L, Nilsson LA. Immunological changes in patients with previous malignant essen-tial hypertension. Lancet 1981;1:406-8.
38. Kuo C, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demostration of Chlamydia pneumoniae in athersclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9.
39. Thom DH, Wang S, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, Weiss NS. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-51.
40. Saikku P, Manila K, Nieminen MS, Huttunen JK, Leinonen M, Ekman MR, Makela PH, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-5.
41. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, Mantarri M, Prick, MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116:273-8.
42. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1993;14:118-23.
43. Thomas CE, Jackson RL, Ohlweiler DF, Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin 1-beta release from human blood mononuclear cells. J Lipid Res 1994;35:417-27.
44. Ku G, Thomas CE, Akeson AL, Jackson RL. Induction of interleukin 1-beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadienoic acid. J Biol Chem 1992;267:14183-9.
45. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:9717-21.
46. Steinbrecher UP, Fisher M, Witztum JL, Curtiss LK. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res 1984;25:1109-16.
47. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol; modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-23.
48. Porter N. Chemistry of lipid peroxidation. In: Packer L, ed. Methods in enzymology, vol 105: oxygen radicals in biological systems. London: Academic Press, 1984:273-82.
49. Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL, McCord JM, Harman D. Oxygen radicals and human disease. Ann Intern Med 1987;107:526-45.
50. Jayakumari N, Ambikakumari V, Balakrishnan KG, Iyer KS. Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis 1992 94:183-90.
51. Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990;280:1-8.
52. Salonen JT, Ylä-Herttuala S, Yammoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
53. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990;114:383-7.
54. Yamamoto A, Hara H, Takaichi S, Wakasugi JI, Tomikawa M. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol 1988;62:31B-6B.
55. O'Brien K, Nagano Y, Gown A, Kita T, Chait A. Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1991;11:751-9.
56. Ku G, Doherty NS, Wolos JA, Jackson RL. Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. Am J Cardiol 1988;62:77B-81B.